

30. The method according to claim 4, wherein the activation of dendritic cells in the presence of a glucocorticoid hormone comprises activating the dendritic cells via a CD40 receptor.

31. The method according to claim 30, wherein activating said dendritic cells through a CD40 receptor involves incubating the dendritic cells with a substance selected from the group consisting of a CD8-40L fusion protein, a trimeric form of CD40L consisting of CD40L molecules to which a modified leucine zipper has been attached, anti-CD40 antibodies, and cells that express CD40L.

32. The method according to claim 30, wherein activating said dendritic cells through a CD40 receptor involves incubation of the dendritic cells with a substance selected from a group consisting of lipopolysaccharide (LPS) and polyI/C.

33. The method according to claim 4, further comprising infecting said dendritic cells with one or more recombinant viruses encoding at least one antigen of interest before activating said dendritic cells in the presence of a glucocorticoid hormone.

34. The method according to claim 4, further comprising incubating said dendritic cells with at least one peptide representing at least one antigen of interest before activating said dendritic cells in the presence of a glucocorticoid hormone.

35. The method according to claim 4, further comprising incubating said dendritic cells with cells containing at least one antigen of interest before activating said dendritic cells in the presence of a glucocorticoid hormone.

36. The method according to claim 4, wherein loading said dendritic cells with an antigen against which said T-cell response is to be reduced comprises loading said dendritic cells with at least one synthetic peptide representing at least one antigen of interest after activating said dendritic cells in the presence of a glucocorticoid hormone.